Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zai Lab (ZLAB) Liabilities and Shareholders Equity (2018 - 2025)

Zai Lab's Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $1.2 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 1.13% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $2.3 billion, down 43.78%, while the annual FY2025 figure was $1.2 billion, 1.13% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.2 billion at Zai Lab, up from $1.2 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.7 billion in Q3 2021 and bottomed at $985.3 million in Q3 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2023), against an average of $1.2 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity grew 24.07% in 2021 before it fell 24.86% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.6 billion in 2021, then fell by 24.21% to $1.2 billion in 2022, then fell by 15.07% to $1.0 billion in 2023, then grew by 14.42% to $1.2 billion in 2024, then dropped by 1.13% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ZLAB's Liabilities and Shareholders Equity are $1.2 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q4 2024).